CareDx, Inc. (CDNA) Earnings Call Transcripts
CareDx, Inc.'s Latest Earnings Call - June 8, 2026
In Q2 2026, CareDx, Inc. focused on its transformation into a precision oncology leader, highlighted by the strategic divestiture of its lab products business and the acquisition of Naveris. Revenue and earnings specifics were not disclosed, but management emphasized the strategic shift towards high-margin, high-growth areas like molecular testing and MRD (Minimal Residual Disease) markets. The divestiture generated $170 million, reinvested into Naveris, aligning with their focus on precision diagnostics. Guidance was not explicitly updated, but the company signaled strong growth prospects in its core areas.
Reported metrics
| Metric | Value |
|---|---|
| Gross Margin | 65% (Naveris), high 70s (Testing Service) (inline) |
| Proceeds from Divestiture | $170 million (positive) |
| Revenue Growth (Naveris) | 70% YoY (positive) |
| Testing Volume Growth | 17% YoY (positive) |
Guidance from management
CareDx plans to launch AlloHeme commercially in Q1 2027 and expects 30-40% growth for Naveris over the next three years. The company anticipates finalizing the MolDX draft LCD in the first half of 2026.
What management said
Yes. They generated 65% margins in the first quarter this year. We're doing the high 70s on our testing service business, and I expect that business to do in the mid-70s long term. We probably have a nice lift, not as much uplift as we have in our CLIA testing on the solid organ side, but we do have a side there. And we think operationally, there are some things we can do at scale at a smaller subscale business can d...
Yes. So we announced that we're reinvesting that in Naveris. So we sold the lab products business for over 3x revenue, and we generated $170 million in proceeds. We'll probably net $160 million after expenses, and that's the price we paid for Naveris. So we feel like it's almost a 1:1 exchange here for a smaller TAM, smaller growth rate, international high regulatory business into CLIA, our business is really CLIA ge...
What analysts pressed on
Analysts are concerned about the competitive landscape in the MRD market and the potential reimbursement impacts from the MolDX draft LCD. Questions focused on the strategic fit of Naveris and the operational challenges of integrating new acquisitions.
Main topics on the call
- Strategic Transformation — CareDx is focusing on precision diagnostics, divesting its lab products business, and acquiring Naveris to enhance its position in MRD markets. CEO John Hanna stated, 'We have really transformed the portfolio of the comp...
- Naveris Acquisition — The acquisition of Naveris, a leader in viral-mediated cancers, is expected to expand CareDx's reach in the MRD market. Hanna noted, 'The Naveris product set, NAV Dx, fit that profile in that it is the market leader in h...
- AlloHeme Development — CareDx is advancing its AlloHeme asset for AML relapse detection, with a planned commercial launch in Q1 2027. Hanna highlighted, 'We found that the test had a really amazing sensitivity and specificity for detecting rel...
- Operational Efficiency — The company is targeting operational efficiencies through Epic integrations and lab consolidations. COO Keith Kennedy mentioned, 'We're hoping to lift from about 4 to 6 a quarter in a privileged world, I'd like to have t...
Read the full CareDx, Inc. transcript (June 8, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About CareDx, Inc.
CareDx, Inc. (CDNA) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGM and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 41 calls on record spanning February 27, 2020 to July 30, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 41 CareDx, Inc. earnings call transcripts on record, spanning February 27, 2020 to July 30, 2026. Based on this history, CareDx, Inc. reports quarterly. The most recent call on file is dated July 30, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- CDNA
- Exchange
- NasdaqGM
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 41
- First call
- February 27, 2020
- Most recent
- July 30, 2026
- Reporting cadence
- quarterly